Jacobs Levy Equity Management
COGT icon

Jacobs Levy Equity Management’s Cogent Biosciences COGT Stock Holding History

Jacobs Levy Equity Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-187,083
Closed -$2.69M – 946
2025
Q3 		$2.69M Buy
+187,083
New +$2.22M 0.01% 535
2019
Q4 		– Sell
-8,249
Closed -$48K – 1006
2019
Q3 		$48K Sell
8,249
-2,945
-26% -$23.9K ﹤0.01% 903
2019
Q2 		$117K Sell
11,194
-16,075
-59% -$214K ﹤0.01% 911
2019
Q1 		$479K Buy
27,269
+14,970
+122% +$256K 0.01% 780
2018
Q4 		$216K Buy
+12,299
New +$364K ﹤0.01% 861

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Jacobs Levy Equity Management's COGT Position: Q4 2025 in Review

Jacobs Levy Equity Management sold out of Cogent Biosciences (COGT) in Q4 2025, closing a stake of 187,083 shares — an estimated $2.69M sold.

Jacobs Levy Equity Management first reported a position in COGT in Q4 2018 and held it in 5 quarters. The position peaked at $2.69M in Q3 2025. 267 funds tracked by Wall St. Rank hold COGT as of Q4 2025.

  • Jacobs Levy Equity Management reported no remaining Cogent Biosciences position as of Q4 2025 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 187,083 Cogent Biosciences shares in Q4 2025, an estimated $2.69M.
  • Jacobs Levy Equity Management first reported a position in Cogent Biosciences in Q4 2018 and held it in 5 quarters.
  • Jacobs Levy Equity Management's Cogent Biosciences position peaked at $2.69M in Q3 2025.
  • 267 funds tracked by Wall St. Rank held Cogent Biosciences as of Q4 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2025, filed 13 Feb 2026.